IL6 and metabolic syndrome: In addition, in the prediabetic and streptozotocin (STZ)-induced diabetic BALB/c mice, the oral administration of ASPs reduced the FBG, alleviated abnormal fasting serum insulin concentrations, decreased the homeostasis model assessment–IR index and body weight, improved the dyslipidemia conditions, reduced serum total cholesterol (TC) or triglyceride (TG) concentrations, increased hepatic glycogen (HG) and muscle glycogen (MG) concentrations, reduced IR-related serum inflammatory factors IL-6 and TNF-α, and restored the impaired pancreatic/hepatic tissues or adipose tissues.